A new research paper was published in Volume 17 of Oncotarget on June 3, 2026, titled "The anticancer effects of PCAIs in ...
Men with a particular form of prostate cancer now have a targeted treatment for the first time, thanks to FDA approval of a ...
Correlation between the number of circulating epithelial tumor cells (CETCs/CTCs) and circulating tumor DNA (ctDNA) in patients with colorectal cancer. This is an ASCO Meeting Abstract from the 2025 ...
Figure 10: Biochemical effects of PCAIs on cancer cells. PCAIs-treated cancer cells show the depletion of the monomeric G-proteins RAC1 and RHOA. MAPK and PI3K/AKT signaling pathways are activated ...
Gedatolisib plus fulvestrant and palbociclib (the “gedatolisib-triplet”) reduced the risk of disease progression or death by 50% vs. alpelisib plus fulvestrant (HR=0.50; 95% CI: 0.37–0.68; p0.0001).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results